alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 65 studies with an author at Chinese University of Hong Kong (HK) (page 2 of 3) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 65 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Benefit-finding intervention for Alzheimer caregivers: conceptual framework, implementation issues, and preliminary efficacy

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Gerontologist 2014-03-31

Controlling for pretest, the benefit-finding group had lower depression than the psychoeducation group at post-test, despite the fact that some caregivers found benefit-finding challenging. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Clinical nutrition (Edinburgh, Scotland) 2011-01-08

Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline. 3 key findings →

Participants: 140 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Benefit-Finding Intervention Delivered Individually to Alzheimer Family Caregivers: Longer-Term Outcomes of a Randomized Double-Blind Controlled Trial

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The journals of gerontology. Series B, Psychological sciences and social sciences 2020-10-01

Benefit-finding is an efficacious intervention for depressive symptoms in Alzheimer caregivers, with strong effects in the medium-term post-intervention and possible moderate effects in the longer-term post-intervention. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A deep‐learning retinal aging biomarker for cognitive decline and incident dementia

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer s & Dementia 2025-03-01

Of 510 memory-clinic subjects(N = 155 cognitive decline), RetiPhenoAge associated with incident cognitive decline (subdistribution hazard ratio [SHR] 1.34, 95% confidence interval [CI] 1.10-1.64, p = 0.004), and incident dementia (SHR 1.43, 95% CI 1.02-2.01, p = 0.036). 5 key findings →

Participants: 155 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Electroacupuncture for older adults with mild cognitive impairment: study protocol for a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Trials 2015-05-27

The study will provide evidence for evaluating and understanding the role of electroacupuncture in the treatment of Alzheimer's disease. 5 key findings →

Participants: 75 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Nature reviews. Disease primers 2018-02-15

The term vascular cognitive impairment (VCI) was introduced around the start of the new millennium and refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-01-10

The prevalences of overall MCI, MCI-A, MCI-CVD, MCI-VRF, and MCI-O were 20.8% (95% confidence interval [CI] = 20.0-21.6%), 6.1% (95% CI = 5.7-6.6%), 3.8% (95% CI = 3.4-4.2%), 4.9% (95% CI = 4.5-5.4%), and 5.9% (95% CI = 5.5-6.4%) respectively. 2 key findings →

Participants: 10,276 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An Ensemble Learning Artificial Intelligence Model for Alzheimer's Disease Detection Using OCT

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Ophthalmology Science 2026-01-10

For detecting AD-dementia, the ensemble model achieved the area under the receiver operating characteristic curve (AUROC) of 0.943 (95% confidence interval, 0.906-0.980), 0.786 (95% confidence interval, 0.673-0.899), and 0.795 (95% confidence interval, 0.716-0.874) in the internal validation, External-1, and External-2, respectively. 4 key findings →

Design: case-control study Participants: 190 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Advancing Alzheimer’s disease risk prediction: development and validation of a machine learning-based preclinical screening model in a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. BMJ Open 2025-02-01

11 variables were critical in the training phase, including educational level, depression, insomnia, age, Body Mass Index (BMI), medication count, gender, stenting, systolic blood pressure (sbp), neurosis and rapid eye movement. 4 key findings →

Design: cross-sectional Participants: 2,379 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Constipation preceding stroke, dementia and Parkinson’s disease in middle-aged and older adults: a population-based cohort study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Age and Ageing 2025-08-29

Out of 462,327 eligible participants, those with constipation were associated with higher incidence of three outcome diseases (1415/20,263 [7.0%]) than those without (18,848/442,064 [4.3%]), with adjusted hazard ratio (HR) being 1.35 [1.27-1.42]. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature communications 2020-09-04

The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovascular dysfunction in neurodegenerative diseases remain elusive. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Montreal Cognitive Assessment: One Cutoff Never Fits All

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Stroke 2015-10-15

The objective of this study is to examine the discrepancy between single versus age and education corrected cutoff scores in classifying performance on the Montreal Cognitive Assessment (MoCA) in patients with stroke or transient ischemic attack. 4 key findings →

Participants: 919 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer's research & therapy 2021-01-12

The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer's disease (AD) is difficult due to the overlaps of clinical symptoms. 4 key findings →

Participants: 47 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Montreal Cognitive Assessment 5-minute protocol is a brief, valid, reliable, and feasible cognitive screen for telephone administration

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Stroke 2015-02-19

The National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization working group proposed a brief cognitive protocol for screening of vascular cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elevated serum inflammasome adaptor protein ASC is associated with white matter hyperintensities in vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Brain Communications 2026-01-01

Alzheimer's disease (AD) and vascular dementia (VaD) exhibit distinct neuropathological hallmarks, with AD defined by cortical amyloid plaques and neurofibrillary tangles, while VaD arises primarily from cerebrovascular disease (CeVD). 4 key findings →

Participants: 531 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of neurology, neurosurgery, and psychiatry 2012-02-22

10 years into PD, a significant proportion of patients developed dopa resistant motor and non-motor features. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Relationship Between Perceived and Objective Financial Abilities Among Older Adults: Results From the Advanced Cognitive Training for Independent and Vital Elderly Cohort

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Gerontologist 2025-04-07

In years when older adults subjectively reported fewer difficulties with their finances, they objectively performed better at financial tasks and this relationship became stronger over 10 years. 5 key findings →

Participants: 2,802 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed